EUCTR2015-002846-30-DK进行中（未招募）1 期
BIO-CHIC-Study BIOmarker driven and dose intensified CHemoImmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk diffuse large B-cell lymphoma - BIO-CHIC
HUS-The Hospital District of Helsinki and Uusimaa0 个研究点目标入组 120 人开始时间: 2016年12月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Age ? 18 - < 65 years
- •Histologically confirmed CD20+ DLBCL based on revised WHO 2008 Lymphoma Classification [51]. The following subgroups and variants can be included:
- •oALK-positive large B-cell lymphoma
- •oIntravascular large B-cell lymphoma
- •oT-cell rich B-cell lymphoma
- •oMyc/BCL-2 double hit lymphoma
- •oFollicular lymphomas grade 3b
- •oDLBCL with previously undiagnosed concurrent small cell infiltration in bone marrow, lymph node, or extranodal site and lymphomas intermediate between DLBCL and Burkitt’s lymphoma are allowed
- •oPosttransplantation lymphoma (PTLD), discordant or transformed lymphoma are NOT allowed
- •Patients in at least stage II with age adjusted IPI score of 2 or 3:
- •oStage III /IV and elevated LDH
- •oStage III/IV and WHO performance status 2 - 3
- •oStage II and elevated LDH and WHO performance status 2 – 3
- •And/or patients with site specific risk factors for CNS recurrence defined as follows
- •oMore than one extranodal site
- •oTesticular lymphoma, stage IIE and higher
- •oParanasal sinus and orbital lymphoma with destruction of bone
- •oLarge cell lymphoma infiltration of the bone marrow
- •Previously untreated, except steroids allowed
- •WHO performance status 0-3
- •Written informed consent
- •Biologically high risk group consists of patients with at least one of the following factor
- •Myc translocation (FISH)
- •Myc/Bcl2 double hits (FISH)
- •P53 deletion (FISH)
- •Myc+/Bcl2+ (IHC)
- •P53+ (ICH)
- •CD5+ (IHC)
- •The biologically low risk group consists of patients without the above listed factors.
- •Paraffin-embedded tumor tissue must be sent to the central laboratory for determination of biological risk factors
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Severe cardiac disease: cardiac function grade 3-4, left ventricular ejection fraction <45%
- •?Impaired bone marrow liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule (Hemoglobin < 9 g/dL, ANC < 1.5 × 109/L, Platelet count < 75 × 109/L, creatinine clearance < 40 mL/min, ALT/AST > 2.5 x ULN, bilirubin >= 1.5 x ULN, INR > 1.5)
- •Pregnancy/lactation
- •Men and women of reproductive potential not agreeing to use effective contraception during treatment and for 18 months after completion of treatment
- •Patients with other severe medical problems, including active infections, cardiac or pulmonary disease, history of PML and with an expected short survival for non-lymphoma reasons
- •Known HIV positivity
- •Active or chronic hepatitis B virus (HBV) infection (defined as positive HBsAg serology), or active hepatitis C virus (HCV) infection (defined by antibody serology testing). HBsAg, HBcAb, and HCVAb must be tested during screening. Patients who have protective titers of HBsAb along negative HBsAg after vaccination or prior but cured hepatitis B are eligible.
- •Vaccination with a live vaccine within one month prior to randomization
- •Patients with a malignancy that has been treated but not with curative intent, unless the malignancy has been in remission without treatment for = 5 years prior to enrollment
- •Earlier treatment containing anthracyclins
- •Psychiatric or mental disorder which make the patient unable to give an informed consent and/or adhere to the protocol
- •CNS disease as diagnosed by MRI or CSF cytology. Positive CSF flow cytometry below diagnostic threshold level by cytology is allowed
- •Transformed lymphoma
- •Primary mediastinal B-cell lymphoma
- •Pleural or peritoneal fluid that cannot be drained safely
- •Hypersensitity to the active substance or any of the other ingredients
- •History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
- •Patients participating in other clinical studies, unless followed for survival
- •Lower urinary tract constriction, which cannot be treated adequately
- •Degenerative and toxic encephalopathy
- •Neuromuscular disease
研究者
相似试验
进行中（未招募）
1 期
Biomarker driven treatment for patients less than 65 years with aggressive B-cell lymphomaEUCTR2015-002846-30-SEHUS-The Hospital District of Helsinki and Uusimaa120
尚未招募
不适用
Biomarker study for postoperative AKI of Emergency surgeryAcute abdomenJPRN-UMIN000037653St marianna University School of Medicine150
进行中（未招募）
1 期
Biomarker driven treatment for patients less than 65 years with aggressive B-cell lymphomaEUCTR2015-002846-30-FIHUS-The Hospital District of Helsinki and Uusimaa120
已完成
不适用
Biomarker study; study to identify biomarkers for protein intake, a randomized, fully controlled feeding studyGeen aandoeningenUitscheiding van biomerkers na het eten van eiwit in het gezond menselijk lichaamBiomarkers of protein intakeNL-OMON36525Wageningen Universiteit25
招募中
不适用
Study of biomarker profiling to unravel the intertwined pathophysiology of coronary artery disease and abdominal aortic aneurysmAbdominal aortic aneurysm10002363NL-OMON53081Erasmus MC, Universitair Medisch Centrum Rotterdam440